Latest Loan Facilities News

Arcadia Minerals reports renewed exploration permits and promising critical mineral anomalies at its Namibian projects, while advancing strategic funding discussions and preparing for key drilling campaigns.

Pearl Gull Iron Limited reported limited exploration activity on Cockatoo Island during the June 2025 quarter, focusing on environmental compliance and native title negotiations, while securing a $500,000 unsecured loan facility to support ongoing operations.

AssetOwl has slashed over $700,000 in debt through a substantial share issuance while reactivating its Pirsee platform to explore new industry applications.

Resolution Minerals has expanded its critical minerals footprint with the acquisition of the Horse Heaven Project in Idaho, complementing its Australian assets and setting the stage for a NASDAQ listing.

Horseshoe Metals has received mining approval for Direct Shipping Ore operations at its Horseshoe Lights project, recommissioned key infrastructure, and secured $851,000 in funding to accelerate near-term copper-gold production.

Kuniko Limited has made steady progress in developing its Norwegian battery metals projects, securing refinancing and preparing a rights issue to fund its next growth phase. Key partnerships and innovative exploration technologies underpin its strategic repositioning.

Althea Group Holdings reported significant cash outflows in Q2 2025 due to one-off costs but anticipates operational improvements and revenue growth from its North American business units.

Cardiex Limited reported a $3 million cash outflow in Q4 2025 but is banking on cost reductions and new product sales to improve its financial footing. The company also secured $6.5 million through a capital raise to bolster its runway.

Wellnex Life Limited reported a robust Q4 FY25 with a 22% sales increase and positive operational cash flow, underpinning its strategic growth initiatives backed by new debt funding.

Admiralty Resources NL reported a cash balance of $1.738 million at the end of June 2025, supported by financing facilities that provide nearly seven quarters of operational funding. The company’s latest cash flow report reveals ongoing investment in exploration alongside careful management of its loan facilities.

Vectus Biosystems confirms safety of its lead fibrosis drug VB0004 from Phase Ia/Ib trials and advances licensing talks globally, including in China, while managing costs and funding challenges.

Ausmon Resources reports promising assay results from recent drilling programs targeting rare earth elements in South Australia and base metals near Broken Hill, NSW, setting the stage for expanded exploration.